|Articles|October 1, 2011
Here Comes the Sun(shine Act)
Drug, biological supply, and medical device manufacturers must track all payments of over $10.
Advertisement
As pharmaceutical, biotechnology, and medical device manufacturers of every kind are discovering in the wake of March 2010's Patient Protection and Affordable Care Act (PPACA), big legislation can mean big change in the world of drug development and clinical trials.
As the healthcare industry initially mobilized to comply with dozens of immediately enforceable changes, even those able to wade through the 2,000-page act may have initially deferred preparation for less urgent provisions—those to be made compulsory eventually, but "not for a few years."
But time moves quickly, and just a few months from now a tiny little statute comprising about 1 percent of the PPACA's text and receiving even less attention from policy analysts will become increasingly prominent in the clinical trials community.
As 22 short pages tucked neatly into the mammoth PPACA, the Physician Payments Sunshine Provision—The Sunshine Act—mandates that drug, biological supply, and medical device manufacturers track all payments of over $10 made to investigators and research sites on an annual basis, beginning on January 1, 2012. This payment information will be reported beginning on March 31, 2013, with records becoming publicly available on September 30, 2013.
So why does this matter to you?
Facing penalties of up to $10,000 per payment omission means that pharmaceutical, biotechnology, and medical device companies need robust methods to track and report physician, vendor, and site payments, now more than ever.
Sponsors may deliver payments to research sites directly or, as is increasingly the norm, outsource their payment management to CROs for service charges of between $100 and $200 per payment. Given the scale of modern clinical trials, delivering, tracking, and reporting thousands of these transactions can turn into a substantial administrative burden and drive significant costs. In light of the Sunshine Act, payment management is also emerging as a regulatory liability.
Whether opting for an in-house or outsourced payment management strategy, the process of delivering, recording, tracking, and reporting site, vendor, and investigator payments has traditionally been undertaken manually, with limited use of automated, web-based resources. But just as technology has emerged to enhance so many other aspects of the clinical trials environment (think CTMS, EDC, IVRS, IWRS, ePRO, etc.), clinical technology developers have recently shifted their focus towards streamlining payment delivery and management processes. By centralizing all payment activity through a web-based system, technology enables detailed tracking and reporting across multiple CROs, vendors, sites, and investigators, where manual processes would be prohibitively costly and alarmingly unreliable.
Efficiently and accurately tracking and reporting site, investigator, and vendor payments is no longer the purview of only internal accounting and finance departments; soon, conformity with Sunshine Act provisions will demand the attention of compliance, regulatory, and top management for pharmaceutical corporations of all sizes and types.
In advance of the Sunshine Act's upcoming commencement, forward-thinking executives should recall the technological innovations now shaping the modern clinical environment and capitalize on the emergence of technology-based solutions for clinical payments.
Samuel Whitaker
CEO Greenphire E-mail: [email protected]
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
- Why Decentralized Trials Face Slow Adoption Despite Strong Data
August 26th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
2
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
3
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
4
How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
5